Veracyte VCYT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Veracyte (VCYT) Business Model and Operations Summary
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Key Insights
Veracyte (VCYT) Core Market Data and Business Metrics
Latest Closing Price
$29.56Market Cap
$2.29 BillionPrice-Earnings Ratio
-227.38Total Outstanding Shares
77.95 Million SharesTotal Employees
824Dividend
No dividendIPO Date
October 30, 2013SIC Description
Services-medical LaboratoriesPrimary Exchange
NASDAQHeadquarters
6000 Shoreline Court, Suite 300, South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-4.63 Million |
| Exchange Gains/Losses | $274,000 |
| Net Cash Flow From Financing Activities, Continuing | $10.06 Million |
| Net Cash Flow From Operating Activities | $66.12 Million |
| Net Cash Flow From Investing Activities | $-4.63 Million |
| Net Cash Flow | $71.83 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $439.09 Million |
| Diluted Earnings Per Share | $-0.13 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Other Operating Expenses | $370.41 Million |
| Revenues | $425.33 Million |
| Benefits Costs and Expenses | $433.50 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $3.65 Million |
| Comprehensive Income/Loss | $3.65 Million |
| Other Comprehensive Income/Loss | $3.65 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $12.91 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $29.90 Million |
| Noncurrent Liabilities | $28.67 Million |
| Wages | $30.74 Million |
| Equity Attributable To Parent | $1.18 Billion |
| Noncurrent Assets | $918.17 Million |
| Assets | $1.28 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||